Concizumab

Summary

Concizumab (CHEMBL4297730) is an approved antibody (ATC B02BX10); indicated across 3 conditions including hemophilia a and hemophilia b.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Antibody
• ATC class: B02BX10
• Indications: 3 conditions
• Clinical trials: 13

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297730
Name	Concizumab
Type	Antibody
Max phase	4
ATC	B02BX10

Also known as: Alhemo, Anti-TFPI, Concizumab, Concizumab-mtci, MAB-2021, NN-7415, NN7415, NNC01722021, mAb2021, CONCIZUMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
hemophilia A	3	MONDO:0010602	MONDO:0010602
hemophilia B	3	MONDO:0010604	MONDO:0010604

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 13.

Phase distribution

Phase	Trials
PHASE1	4
Not specified	4
PHASE3	3
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04082429	PHASE3	ACTIVE_NOT_RECRUITING	Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors
NCT04083781	PHASE3	ACTIVE_NOT_RECRUITING	Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia With Inhibitors
NCT05135559	PHASE3	ACTIVE_NOT_RECRUITING	A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors
NCT03196284	PHASE2	COMPLETED	A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors
NCT03196297	PHASE2	COMPLETED	A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors
NCT01228669	PHASE1	COMPLETED	Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or B
NCT01555749	PHASE1	COMPLETED	Investigation of the Pharmacokinetics of NNC172-2021, at Two Different Dose Levels, in Healthy Japanese Subjects
NCT01631942	PHASE1	TERMINATED	A Multi-centre, Open Labelled, Multiple Dosing Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC 0172-2021 Administered Subcutaneously to Healthy Male Subjects and Haemophilia Subjects
NCT02490787	PHASE1	COMPLETED	Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects
NCT04921956	Not specified	AVAILABLE	Compassionate Use of Concizumab if You Have Haemophilia
NCT06285071	Not specified	ENROLLING_BY_INVITATION	Post-Marketing Surveillance (All Case Surveillance) on Treatment With Alhemo® in Patients With Haemophilia A or Haemophilia B With Inhibitors
NCT06831734	Not specified	ENROLLING_BY_INVITATION	Post-marketing Surveillance (Special Use-results Surveillance) on Treatment With Alhemo
NCT06234813	Not specified	COMPLETED	Targeting TFPI With Concizumab to Improve Haemostasis in Glanzmann Thrombasthenia Patients: an in Vitro Study

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).